Russian Severe Asthma Registry
Russian Severe Asthma Registry
The Russian Severe Asthma Registry is a Russian initiative to collect anonymous long-term
 evidence for patients with severe asthma in Russia
The Russian Severe Asthma Registry is a Russian initiative to collect anonymous long-term
 evidence for patients with severe asthma in Russia. The RSAR initiative is realized under the
 efforts of the Interregional Public Organization "Russian Respiratory Society" and LLC "RSMI"
 with the sponsorship of "AstraZeneca Pharmaceuticals" LLC.

 The developed RSAR electronic database is a Russian software product that meets the current
 requirements of the Russian legislation in the field of working with personal data and the
 implementation of similar observational studies.

 Participating researchers also agree to grant access and share anonymous data at the patient
 level as part of the work to implement the RSAR initiative. Participants will provide
 high-quality data for the development of data sets for research, approved by the Russian
 Respiratory Society (RPO), which has priority in owning and implementation in scientific
 field of the gained data. Based on ethical, legal and regulatory authorizations, anonymous
 data will be collected in the Central Database (CDB) on respiratory diseases (referred to
 here as the RSAR database) to create sets of important data and the necessary analysis. CDB
 is part of the software "Medical online platform ROSMED.INFO".
Inclusion Criteria:

 -  Patients aged 12 years or older.

 -  Patients with confirmed diagnosis of severe asthma.

 -  Patients receiving treatment according to GINA step 5 or uncontrolled for 4 step.
 Uncontrolled patients are defined as having symptoms of severe asthma or frequent
 exacerbations .

 -  Signed informed consent.

 Exclusion Criteria:

 -  Patients currently participating in clinical trials at the time of enrolment

 -  Intermittent, mild, moderate BA, before verification of the diagnosis.

 -  COPD.

 -  Diseases of the respiratory system, such as tuberculosis, sarcoidosis, IPF, lung
 cancer.

 -  Vasculitis, systemic connective tissue diseases.

 -  Neoplasm.

 -  Written refusal of the patient to participate in the study after signing an
 informed consent.